

Interactions with Key COVID-19 Therapies

Revised January 2026

Page 1 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Contents

ADHD Agents.....	2	Cough and Cold Preparations	32
Anaesthetics & Muscle Relaxants	3	Covid-19 Antiviral Therapies	33
Analgesics.....	4	Covid-19 Host-directed Therapies	34
Antiarrhythmics	5	Cystic Fibrosis Agents.....	35
Antibacterials.....	6	Dementia Therapies	36
Anti-coagulant, Anti-platelet and Fibrinolytic	7	Erectile Dysfunction Agents	37
Anticonvulsants.....	8	Gastrointestinal Agents.....	38
Antidepressants	9	Gastrointestinal Agents – Anti-emetics	39
Anti-diabetics	10	HCV DDAs	40
Antifungals	11	HIV Antiretroviral Therapies	41
Antihaemorrhagics.....	12	Hypertensives – ACE inhibitors	42
Antihistamines	13	Hypertensives – Angiotensin antagonists.....	42
Antimalarials	14	Hypertensives – Diuretics	43
Antimigraine Agents	15	Hypertensives – Other agents.....	44
Antipsychotics/Neuroleptics.....	16	Hypertensives – Pulmonary hypertension	45
Antivirals	17	Illicit/Recreational	46
Anxiolytics/Hypnotics/Sedatives	18	Immune Modulators	47
Benign Prostatic Hyperplasia Therapies	19	Immunosuppressants.....	48
Beta Blockers	20	Inotropes & Vasopressors.....	49
Bisphosphonates.....	21	Lipid Lowering Agents	50
Bronchodilators	22	Multiple Sclerosis Agents	51
Calcium Channel Blockers.....	23	Ophthalmological Agents.....	52
Cancer Therapies (A-B)	24	Others (A-F).....	53
Cancer Therapies (C-D)	25	Others (G-O).....	54
Cancer Therapies (E-H)	26	Others (P-Z)	55
Cancer Therapies (I-O)	27	Overactive Bladder Agents.....	56
Cancer Therapies (P-S).....	28	Parkinsonism Agents.....	57
Cancer Therapies (T-Z)	29	Steroids	58
Contraceptives/HRT - Contraceptives.....	30	Vitamins/Supplements/Herbals.....	59
Contraceptives/HRT - Hormone Replacement Therapy ...	31		

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

■	These drugs should not be coadministered
■	Potential interaction which may require a dose adjustment or close monitoring.
■	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
■	No clinically significant interaction expected

Check for Updates

Using a saved or printed version? Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 2 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made.

Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

ADHD Agents

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Amphetamine mixed salts	↔	↔	↑	↑	↔	↔	↔	↔	↔	↔
Atomoxetine	↑	↔	↑	↑	↔ ♥	↔	↔	↔	↔	↔
Dexamfetamine	↔	↔	↑	↑	↔	↔	↔	↔	↔	↔
Dexmethylphenidate	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Guanfacine	↑	↔	↑	↑	↔ ♥	↔	↔	↔	↔	↔
Lisdexamfetamine	↔	↔	↑	↑	↔	↔	↔	↔	↔	↔
Methylphenidate	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Serdexmethylphenidate	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

Ensitrelvir or Nirmatrelvir/ritonavir + Atomoxetine

A clinically significant interaction is not expected in extensive metabolizers of CYP2D6. However, atomoxetine concentrations may increase in poor CYP2D6 metabolizers and caution is advised.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 3 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Anaesthetics & Muscle Relaxants

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Alcuronium	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Bupivacaine	↑	↔	↑	↑	↔	↔	↔	↔	↔	↓
Cisatracurium	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Cyclobenzaprine	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Desflurane	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Dexmedetomidine	↔	↔	↔	↓	↔♥	↔	↔	↔	↔	↔
Enflurane	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Ephedrine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Esketamine (anaesthetic)	↑	↔	↑	↑						
Etidocaine	↑	↔	↑	↑	↔	↔	↔	↔	↔	↓
Halothane	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Isoflurane	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Ketamine	↑	↔	↑	↑	↔	↔	↔	↔	↔	↓
Methocarbamol	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Nitrous oxide	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Propofol	↔	↔	↔	↓	↔♥	↔	↔	↔	↔	↔
Rocuronium	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Ropivacaine	↔	↔	↔	↓	↔	↔	↔	↔	↔	↔
Sevoflurane	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Sufentanil	↑	↔	↑	↑	↔	↔	↔	↔	↔	↓
Suxamethonium (succinylcholine)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Tetracaine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Thiopental	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Tizanidine	↔	↔	↔	↓	↔♥	↔	↔	↔	↔	↔
Vecuronium	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 4 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Analgesics

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Alfentanil	↑	↔	↑	↑	↔	↔	↔	↔	↔	↓
Aspirin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Buprenorphine	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↓
Butalbital	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Celecoxib	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Codeine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Dexketoprofen	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Dextropropoxyphene	↑	↔	↑	↑	↔	↔	↔	↔	↔	↓
Diamorphine (diacetylmorphine)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Diclofenac	↔	↔	↔	↔	↔	↔	↔	↔	↑	↔
Dihydrocodeine	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Etoricoxib	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Fentanyl	↑	↔	↑	↑	↔	↔	↔	↔	↔	↓
Hydrocodone	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Hydromorphone	↔	↔	↓	↓	↔	↔	↔	↔	↔	↔
Ibuprofen	↔	↔	↔	↔	↔	↔	↔	↔	↑	↔
Indometacin (Indomethacin)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Ketoprofen	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Ketorolac	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Lornoxicam (Chlortenoxicam)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Mefenamic acid	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Meloxicam	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Metamizole	↑↓	↔	↑↓	↑↓	↔	↓	↓	↓	↔	↔
Methadone	↑	↔	↓	↓	↔♥	↔	↔	↔	↔	↔
Morphine	↔	↔	↔	↓	↔	↔	↔	↔	↔	↔
Nabumetone	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Naproxen	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Nefopam	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Nimesulide	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Oxycodone	↑	↔	↑	↑	↔	↔	↔	↔	↔	↓
Paracetamol (Acetaminophen)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Pethidine (Meperidine)	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Piroxicam	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Remifentanyl	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Tapentadol	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Tramadol	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

Codeine + Nirmatrelvir/ritonavir

Ritonavir could potentially reduce the analgesic efficacy.

Diamorphine, Morphine + Nirmatrelvir/ritonavir

Coadministration may potentiate the effects of opiate in the CNS (via inhibition of P-gp at the blood-brain barrier). Monitor for opiate toxicity.

Aspirin, Celecoxib, Dexketoprofen, Diclofenac, Etoricoxib, Ibuprofen, Indometacin, Ketoprofen, Ketorolac, Lornoxicam, Mefenamic acid,

Meloxicam, Nabumetone, Naproxen, Nimesulide, Piroxicam + Dexamethasone, Hydrocortisone, Methylprednisolone

Patients should be monitored since the incidence and/or severity of gastro-intestinal ulceration may increase.

Metamizole + Baricitinib, Tocilizumab

Coadministration should be avoided due to the increased risk of haematological toxicity.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 5 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made.

Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Antiarrhythmics

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Amiodarone	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↓
Bepiridil	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Digoxin	↑ 31%	↔	↑	↑	↔	↔	↔	↔	↓ 10%	↔
Disopyramide	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Dofetilide	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Dronedarone	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Flecainide	↔	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Lidocaine (Lignocaine)	↔	↔	↑	↑	↔	↔	↔	↔	↔	↔
Mexiletine	↔	↔	↑	↑	↔	↔	↔	↔	↔	↔
Procainamide	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Propafenone	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Quinidine	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↓

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

- Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.
- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

Dexamethasone, Hydrocortisone, Methylprednisolone

Close monitoring is advised as dexamethasone, hydrocortisone or methylprednisolone may cause hypokalaemia which increases the risk of arrhythmias. In cases of hypokalaemia, potassium levels should be corrected and QT interval monitored.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 6 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Antibacterials

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Azithromycin	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Bedaquiline	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Ciprofloxacin	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Clarithromycin	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Clindamycin	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Delamanid	↑♥	↔	↑♥	↑♥	↔♥	↔	↔	↔	↔	↔
Erythromycin	↑♥	↔	↑♥	↑♥	↔♥	↔	↔	↔	↔	↔
Fusidic acid (oral or IV)	↑	↔	↑↑	↑↑	↔	↔	↔	↔	↔	↔
Gemifloxacin	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Levofloxacin	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Linezolid	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Moxifloxacin	↔	↔	↔	↓	↔♥	↔	↔	↔	↔	↔
Nafcillin	↓	↔	↓	↓	↔	↓	↓	↓	↔	↔
Ofloxacin	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Rifabutin	↑	↔	↑	↑	↔	↓	↓	↓	↔	↔
Rifampicin (Rifampin)	↓	↔	↓	↓	↓	↓	↓	↓	↓ 34%	↔
Rifapentine	↓	↔	↓	↓	↓	↓	↓	↓	↔	↔
Roxithromycin	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Teicoplanin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Telavancin	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Telithromycin	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Tinidazole	↔	↔	↔	↑	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑↑ Potential increased exposure of COVID drug
- ↓↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

- Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.
- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

Linezolid, Nafcillin, Teicoplanin + Baricitinib, Tocilizumab

Caution is required due to potential additive haematological toxicity.

No interactions are expected with the COVID-19 therapies listed and the following antibacterials:

- | | | |
|-----------------|------------------------|-------------------------------|
| Amikacin | Dapsone | Metronidazole |
| Amoxicillin | Doxycycline | Minocycline |
| Ampicillin | Ertapenem | Neomycin |
| Capreomycin | Ethambutol | Nitrofurantoin |
| Cefalexin | Ethionamide | Para-aminosalicylic acid |
| Cefazolin | Flucloxacillin | Penicillins |
| Cefepime | Furazolidone | Piperacillin |
| Cefixime | Fosfomycin | Pyrazinamide |
| Cefotaxime | Fusidic acid (topical) | Rifaximin |
| Ceftazidime | Gatifloxacin (topical) | Spectinomycin |
| Ceftriaxone | Gentamicin | Streptomycin |
| Cefuroxime | Imipenem/Cilastatin | Sulfadiazine |
| Chloramphenicol | Isoniazid | Tazobactam |
| Clavulanic acid | Kanamycin | Tetracyclines |
| Clofazimine | Lymecycline | Tobramycin |
| Cloxacinil | Meropenem | Trimethoprim/Sulfamethoxazole |
| Cycloserine | | Vancomycin |

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 7 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Anti-coagulant, Anti-platelet and Fibrinolytic

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Acenocoumarol	↔	↔	↓	↓	↔	↔	↔	↔	↔	↓
Apixaban	↑	↔	↑	↑	↔	↓	↔	↔	↔	↓
Argatroban	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Aspirin (anti-platelet)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Betrixaban	↑	↔	↑	↑	↔♥	↓	↔	↔	↔	↔
Cilostazol	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Clopidogrel	↓	↔	↓	↓	↔	↔	↔	↔	↔	↓
Clopidogrel (recently stented patients)	↓	↔	↓	↓	↔	↔	↔	↔	↔	↓
Dabigatran	↑	↔	↔	↔	↔	↓	↔	↔	↔	↔
Dalteparin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Dipyridamole	↔	↔	↔	↓	↔	↔	↔	↔	↔	↔
Edoxaban	↑	↔	↑	↑	↔	↓	↔	↔	↔	↔
Enoxaparin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Fondaparinux	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Heparin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Nadroparin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Phenprocoumon	↑	↔	↓	↓↑	↔	↔	↔	↔	↔	↓
Prasugrel	↔	↔	↔	↔	↔	↔	↔	↔	↔	↓
Rivaroxaban	↑	↔	↑	↑	↔	↓	↔	↔	↔	↓
Streptokinase	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Ticagrelor	↑	↔	↑	↑	↔	↔	↔	↔	↔	↓
Ticlopidine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Tinzaparin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Vorapaxar	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Warfarin	↑	↔	↓	↓	↔	↔	↔	↔	↔	↓

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑↑ Potential increased exposure of COVID drug
- ↓↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

- Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.
- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

Acenocoumarol, Phenprocoumon, Warfarin + Tocilizumab

Monitor INR with vitamin K antagonists (e.g., acenocoumarol, phenprocoumon, warfarin).

Acenocoumarol, Phenprocoumon, Warfarin + Dexamethasone, Hydrocortisone, Methylprednisolone

Efficacy of coumarin anticoagulants may be enhanced by concurrent corticosteroid therapy and close monitoring of the INR or prothrombin time is required to avoid spontaneous bleeding.

Apixaban, Betrixaban, Dabigatran, Edoxaban, Rivaroxaban + Dexamethasone

COVID-19 is associated with hypercoagulopathy and an excess of thrombotic complications. Alternatives, e.g., low molecular weight heparins, may be considered in severe COVID19 disease. Note, any reduction in drug concentrations may persist for up to 14 days after dexamethasone course is complete.

Apixaban, Argatroban, Betrixaban, Dabigatran, Edoxaban, Rivaroxaban + Methylprednisolone

There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids. Therefore, coagulation indices should be monitored to maintain the desired anticoagulant effects.

Aspirin (anti-platelet) + Dexamethasone, Hydrocortisone, Methylprednisolone

Product labels for aspirin advise caution in patients receiving concomitant medications which could increase the risk of ulceration, e.g., oral corticosteroids.

Cilostazol, Ticlopidine + Dexamethasone, Hydrocortisone, Methylprednisolone

Caution is required due to potential additive haematological toxicity.

Clopidogrel (± recently stented patients) + Nirmatrelvir/ritonavir

Management of this interaction should take into account whether or not a transient loss of clopidogrel efficacy during the short duration of nirmatrelvir/ritonavir treatment is acceptable. Avoid coadministration in patients at very high-risk of thrombosis, e.g. at least within 6 weeks of coronary stenting. A transient loss in efficacy may be acceptable in other clinical situations, allowing clopidogrel to continue.

Dabigatran + Nirmatrelvir/ritonavir

No pharmacokinetic interaction expected if nirmatrelvir/ritonavir is administered **simultaneously** with dabigatran.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 8 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Anticonvulsants

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Brivaracetam	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Carbamazepine	↓	↔	↓	↓	↓	↓	↓	↓	↔	↓
Cenobamate	↓	↔	↓	↓	↓	↓	↓	↓	↑	↔
Clonazepam	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Eslicarbazepine	↓↑	↔	↓↑	↓↑	↔	↓	↓	↓	↔	↔
Ethosuximide	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Felbamate	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Fosphenytoin	↓	↔	↓	↓	↓	↓	↓	↓	↔	↓
Gabapentin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Lacosamide	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Lamotrigine	↔	↔	↓	↓	↔	↔	↔	↔	↔	↔
Levetiracetam	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Oxcarbazepine	↓↑	↔	↓↑	↓↑	↔	↓	↓	↓	↔	↔
Perampanel	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Phenobarbital (Phenobarbitone)	↓	↔	↓	↓	↓	↓	↓	↓	↔	↓
Phenytoin	↓	↔	↓	↓	↓	↓	↓	↓	↔	↓
Pregabalin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Primidone	↓	↔	↓	↓	↓	↓	↓	↓	↔	↓
Retigabine	↔	↔	↓	↓	↔	↔	↔	↔	↔	↔
Rufinamide	↓	↔	↓	↓	↔	↓	↓	↓	↔	↔
Sodium valproate	↔	↔	↓	↓	↔	↔	↔	↔	↔	↔
Sultiame	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Tiagabine	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Topiramate	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Valproate semisodium (Divalproex)	↔	↔	↓	↓	↔	↔	↔	↔	↔	↔
Valproic acid	↔	↔	↓	↓	↔	↔	↔	↔	↔	↔
Vigabatrin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Zonisamide	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑↑ Potential increased exposure of COVID drug
- ↓↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

Eslicarbazepine and Oxcarbazepine + Nirmatrelvir/ritonavir

Ritonavir could increase eslicarbazepine and oxcarbazepine concentrations in the brain due to inhibition of P-gp, particularly in drug-resistant patients on high dose eslicarbazepine or oxcarbazepine and potentially cause adverse effects (drowsiness, diplopia, dizziness, nausea and vomiting). The clinical relevance of this interaction is unclear in patients on standard doses of eslicarbazepine or oxcarbazepine but use with caution in patients on high dose eslicarbazepine or oxcarbazepine.

Felbamate + Baricitinib, Tocilizumab

Caution is required due to potential additive haematological toxicity. Felbamate is associated with a marked increase in the incidence of aplastic anaemia.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 9 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Antidepressants

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Agomelatine	↔	↔	↔	↓	↔	↔	↔	↔	↔	↔
Amitriptyline	↔	↔	↑	↑	↔	↔	↔	↔	↔	↔
Amoxapine	↔	↔	↑	↑	↔	↔	↔	↔	↔	↔
Bupropion	↔	↔	↓	↓	↔	↔	↔	↔	↔	↔
Citalopram	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Clomipramine	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Desipramine	↔	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Desvenlafaxine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Doxepin	↔	↔	↑	↑	↔	↔	↔	↔	↔	↔
Duloxetine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Escitalopram	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Esketamine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Fluoxetine	↔	↔	↑	↑	↔	↔	↔	↔	↔	↔
Imipramine	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Lithium	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Maprotiline	↔	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Mianserin	↔	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Milnacipran	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Mirtazapine	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Moclobemide	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Nefazodone	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Nortriptyline	↔	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Opipramol	↔	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Paroxetine	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Phenelzine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Reboxetine	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Sertraline	↔	↔	↔	↓	↔	↔	↔	↔	↔	↔
Tranlycypromine	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Trazodone	↑♥	↔	↑♥	↑♥	↔	↔	↔	↔	↔	↔
Trimipramine	↔	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Venlafaxine	↔	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Vilazodone	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Vortioxetine	↔	↔	↑	↑	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

Lithium + Dexamethasone, hydrocortisone, methylprednisolone

If electrolyte imbalance occurs with dexamethasone, hydrocortisone or methylprednisolone, there is potential for altered lithium excretion. The clinical significance of this is unclear but monitoring of lithium effects may be required, particularly in patients with renal impairment or with other conditions pre-disposing to lithium toxicity.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 10 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Anti-diabetics

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Acarbose	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Alogliptan	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Canagliflozin	↔	↔	↔	↓	↔	↔	↔	↔	↔	↔
Dapagliflozin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Dulaglutide	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Empagliflozin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Exenatide	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Glibenclamide (Glyburide)	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Gliclazide	↔	↔	↔	↓	↔	↔	↔	↔	↔	↔
Glimepiride	↔	↔	↔	↓	↔	↔	↔	↔	↔	↔
Glipizide	↔	↔	↔	↓	↔	↔	↔	↔	↔	↔
Insulin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Linagliptin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Liraglutide	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Metformin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Nateglinide	↔	↔	↑	↑↓	↔	↔	↔	↔	↔	↔
Pioglitazone	↔	↔	↔	↑	↔	↔	↔	↔	↔	↔
Repaglinide	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Rosiglitazone	↔	↔	↔	↓	↔	↔	↔	↔	↔	↔
Saxagliptin	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Semaglutide	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Sitagliptin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Tirzepatide	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Tolbutamide	↔	↔	↔	↓	↔	↔	↔	↔	↔	↔
Vildagliptin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑↑ Potential increased exposure of COVID drug
- ↓↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

Antidiabetics (if amber) + Nirmatrelvir/ritonavir

Patients should be advised to monitor blood sugar levels at home.

Antidiabetics + Dexamethasone or hydrocortisone

The desired effects of hypoglycaemic agents can be antagonised by dexamethasone or hydrocortisone and blood glucose monitoring is recommended.

Antidiabetics + Methylprednisolone

Corticosteroids may increase blood glucose concentrations and dosage adjustments of antidiabetic agents may be required.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Amber	Potential interaction which may require a dose adjustment or close monitoring.
Light Green	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
White	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 11 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Antifungals

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Amphotericin B	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Anidulafungin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Caspofungin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Clotrimazole (pessary, troche)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Clotrimazole (topical)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Fluconazole	↔	↔	↔	↔	↔♥	↔	↔	↔	↑ 22%	↔
Flucytosine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Griseofulvin	↓	↔	↓	↓	↔	↓	↓	↓	↔	↔
Isavuconazole	↑	↔	↑↓	↑↓	↔	↔	↔	↔	↔	↔
Itraconazole	↑↑	↔	↑↑	↑↑	↔	↔	↔	↔	↔	↔
Ketoconazole	↑	↔	↑	↑	↔	↔	↔	↔	↑ 21%	↔
Micafungin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Miconazole	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Nystatin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Posaconazole	↑↑	↔	↑↑	↑↑	↔	↔	↔	↔	↔	↔
Rezafungin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Terbinafine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Voriconazole	↑↑	↔	↑↓	↑↓	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑↑ Potential increased exposure of COVID drug
- ↓↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

- Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.
- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

Amphotericin B + Dexamethasone, Hydrocortisone, Methylprednisolone

Close monitoring is advised as dexamethasone, hydrocortisone, methylprednisolone and amphotericin may cause hypokalaemia which increases the risk of torsade de pointes. Before the start of corticosteroid treatment, hypokalaemia should be corrected and patients should be monitored clinically, for electrolytes and by ECG.

Voriconazole + Nirmatrelvir/ritonavir

Voriconazole concentrations may decrease in individuals with functional CYP2C19 or increase in individuals with loss-of-function in CYP2C19.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 12 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Antihaemorrhagics

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Avatrombopag	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Eltrombopag	↔	↔	↓	↓	↔	↔	↔	↔	↔	↔
Emicizumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Fostamatinib	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Tranexamic acid	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

Baricitinib, Tocilizumab: Caution is required due to potential additive haematological toxicity.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version? Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 13 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Antihistamines

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Azelastine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Bilastine	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Cetirizine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Chlorphenamine	↔	↔	↔	↑	↔	↔	↔	↔	↔	↔
Clemastine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Desloratadine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Diphenhydramine	↔	↔	↔	↑	↔	↔	↔	↔	↔	↔
Doxylamine	↔	↔	↔	↑↓	↔	↔	↔	↔	↔	↔
Fexofenadine	↔	↔	↔	↑	↔	↔	↔	↔	↔	↔
Levocetirizine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Loratadine	↑	↔	↔	↑	↔	↔	↔	↔	↔	↔
Meclizine	↔	↔	↔	↑	↔	↔	↔	↔	↔	↔
Promethazine	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

- Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.
- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 14 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Antimalarials

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Amodiaquine	↔	↔	↓	↓	↔	↔	↔	↔	↔	↔
Artemether	↓	↔	↓	↓	↔	↔	↔	↔	↔	↔
Artesunate	↔	↔	↓	↓	↔	↔	↔	↔	↔	↔
Atovaquone	↔	↔	↔	↓	↔	↔	↔	↔	↔	↔
Chloroquine	↑♥	↔	↑♥	↑♥	↓♥	↔	↔	↔	↔	↔
Halofantrine	↑♥	↔	↑♥	↑♥	↔♥	↔	↔	↔	↔	↓
Hydroxychloroquine	↑	↔	↑	↑	↓♥	↔	↔	↔	↔	↔
Lumefantrine	↑♥	↔	↑♥	↑♥	↔♥	↔	↔	↔	↔	↔
Mefloquine	↑	↔	↓↓	↓↓	↔	↔	↔	↔	↔	↔
Piperaquine	↑♥	↔	↑♥	↑♥	↔♥	↔	↔	↔	↔	↔
Primaquine	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Proguanil	↔	↔	↔	↓	↔	↔	↔	↔	↔	↔
Pyrimethamine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Quinine	↑♥	↔	↑♥	↑♥	↔	↔	↔	↔	↔	↔
Sulfadoxine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

Chloroquine or Hydroxychloroquine + Baricitinib, Tocilizumab
Use with caution due to potential additive toxicity.

Chloroquine or Hydroxychloroquine + Dexamethasone, Hydrocortisone, Methylprednisolone
Caution is recommended as there is an increased risk of myopathies

Primaquine or Pyrimethamine + Baricitinib, Tocilizumab
Caution is required due to potential additive haematological toxicity.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 15 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Antimigraine Agents

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Almotriptan	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Atogepant	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Dihydroergotamine	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Eletriptan	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Eptinezumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Erenumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Ergotamine	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Fremanuzemab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Frovatriptan	↔	↔	↔	↓	↔	↔	↔	↔	↔	↔
Galcanezumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Methysergide	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Naratriptan	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Pizotifen	↔	↔	↔	↓	↔	↔	↔	↔	↔	↔
Rimegepant	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Rizatriptan	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Sumatriptan	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Ubrogepant	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Zolmitriptan	↔	↔	↑	↑	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

- Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.
- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 16 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Antipsychotics/Neuroleptics

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Amisulpride	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Aripiprazole	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Asenapine	↔	↔	↔	↓	↔	↔	↔	↔	↔	↔
Brexpiprazole	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Cariprazine	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Chlorpromazine	↔	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Clozapine	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Flupentixol (Flupenthixol)	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Fluphenazine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Haloperidol	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Iloperidone	↑♥	↔	↑♥	↑♥	↔♥	↔	↔	↔	↔	↔
Levomepromazine	↔	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Lumateperone	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Lurasidone	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Olanzapine	↔	↔	↔	↓	↔	↔	↔	↔	↔	↔
Paliperidone	↔	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Perazine	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Periciazine	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Perospirone	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Perphenazine	↔	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Pimavanserin	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Pimozide	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Pipotiazine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Quetiapine	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Risperidone	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Sertindole	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Sulpiride	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Thioridazine	↑	↔	↑	↑	↔♥	↓	↓	↓	↔	↔
Tiapride	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Ziprasidone	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Zotepine	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Zuclopenthixol	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

- Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.
- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

Brexpiprazole, Cariprazine, Clozapine and Lumateperone + Baricitinib, Tocilizumab
Caution is required due to potential additive haematological toxicity.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 17 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Antivirals

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Aciclovir	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Adefovir	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Baloxavir	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Brincidofovir	↔	↔	↑	↑	↔	↔	↔	↔	↑	↔
Bulevirtide	↔	↔	↑	↑	↔	↔	↔	↔	↔	↔
Cidofovir	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Entecavir	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Famciclovir	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Foscarnet	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Ganciclovir	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Letermovir	↔	↔	↔	↓	↔	↔	↔	↔	↑	↔
Maribavir	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Oseltamivir	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Ribavirin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Rimantadine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Tecovirimat	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Telbivudine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Tenofovir alafenamide (HBV)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Valaciclovir (Valacyclovir)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Valganciclovir	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Zanamivir	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined.

Note, please check product labels for any additional cardiac warnings.

Notes:

Ganciclovir, Valganciclovir + Baricitinib, Tocilizumab

Caution is required due to potential additive haematological toxicity.

Ribavirin + Baricitinib

Use with caution due to potential additive haematological toxicity.

Ribavirin + Tocilizumab

The risk of haematological toxicity may be potentially increased as ribavirin and tocilizumab can cause myelosuppression. Closely monitor haematological parameters.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 18 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Anxiolytics/Hypnotics/Sedatives

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Alprazolam	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Bromazepam	↑	↔	↔	↑	↔	↔	↔	↔	↔	↔
Buspirone	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Chlordiazepoxide	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Clobazam	↑	↔	↑↓	↑↓	↔	↔	↔	↔	↔	↔
Clorazepate	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Daridorexant	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Diazepam	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Estazolam	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Eszopiclone	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Flunitrazepam	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Flurazepam	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Hydroxyzine	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Lorazepam	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Lormetazepam	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Midazolam (buccal)	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Midazolam (oral)	↑ 577%	↔	↑	↑	↔	↔	↔	↔	↔	↔
Midazolam (parenteral)	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Oxazepam	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Secobarbital	↑	↔	↑	↑	↔	↔	↔	↔	↔	↓
Suvorexant	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Temazepam	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Triazolam	↑	↔	↑	↑	↔	↓ 19%	↔	↔	↔	↔
Zaleplon	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Zolpidem	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Zopiclone	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

- Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.
- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

Hydroxyzine, Zolpidem, Zopiclone + Nirmatrelvir/ritonavir
Patients should be advised of the risk of increased sedation.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 19 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Benign Prostatic Hyperplasia Therapies

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Alfuzosin	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Dutasteride	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Finasteride (5 mg)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Silodosin	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Tadalafil (BPH)	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Tamsulosin	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

- Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.
- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 20 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Beta Blockers

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Atenolol	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Bisoprolol	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Carvedilol	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Metoprolol	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Nebivolol	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Oxprenolol	↔	↔	↔	↓	↔♥	↔	↔	↔	↔	↔
Pindolol	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Propranolol	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Sotalol	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Timolol	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 21 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Bisphosphonates

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Alendronic acid (Alendronate)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Ibandronic acid (Ibandronate)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Risedronic acid (Risedronate)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Zoledronic acid (Zoledronate)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

■	These drugs should not be coadministered
■	Potential interaction which may require a dose adjustment or close monitoring.
■	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
■	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 22 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Bronchodilators

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Acclidinium bromide	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Aminophylline	↔	↔	↓	↓	↔	↔	↔	↔	↔	↓
Formoterol	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Glycopyrronium bromide	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Indacaterol	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Ipratropium bromide	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Montelukast	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Olodaterol	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Roflumilast	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Salbutamol	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Salmeterol	↑♥	↔	↑♥	↑♥	↔	↔	↔	↔	↔	↔
Terbutaline	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Theophylline	↔	↔	↓	↓	↔	↔	↔	↔	↔	↓
Tiotropium bromide	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Umeclidinium bromide	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Vilanterol	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Zafirlukast	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

- Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.
- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

Aminophylline + Nirmatrelvir/ritonavir or Tocilizumab

Aminophylline is a complex of theophylline and ethylenediamine and is given for its theophylline activity. Coadministration may decrease theophylline concentrations.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 23 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made.

Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Calcium Channel Blockers

	ESV	Antivirals				Corticosteroids			Host-directed	
		MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Amlodipine	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Barnidipine	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Diltiazem	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Felodipine	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Nicardipine	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Nifedipine	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Nimodipine	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Nisoldipine	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Nitrendipine	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Verapamil	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

Calcium channel blockers + Nirmatrelvir/ritonavir

A dose adjustment could be optional given that patients can be advised to monitor for symptoms of hypotension, flushing and oedema and, if necessary, to temporarily pause the antihypertensive drug.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 24 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Cancer Therapies (A-B)

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Abemaciclib	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Abiraterone	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Acalabrutinib	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Afatinib	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Aldesleukin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Alectinib	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Alpelisib	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Amivantamab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Anastrozole	↑	↔	↑	↑↓	↔	↔	↔	↔	↔	↔
Apalutamide	↓	↔	↓	↓	↓♥	↓	↓	↓	↔	↔
Arsenic trioxide	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Asciminib	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Atezolizumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Avapritinib	↑	↔	↑	↑	↔♥	↓	↓	↓	↔	↔
Avelumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Axitinib	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Azacitidine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Bendamustine	↑	↔	↔	↓	↔♥	↔	↔	↔	↔	↔
Bevacizumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Bexarotene	↓	↔	↓	↓	↔	↓	↓	↓	↔	↔
Bicalutamide	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Binimetinib	↔	↔	↔	↓	↔	↔	↔	↔	↑	↔
Blinatumomab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Bortezomib	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Bosutinib	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Brentuximab vedotin	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Brigatinib	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Busulfan	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

- Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.
- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

Baricitinib, tocilizumab: Caution is required due to potential additive haematological toxicity.

Aldesleukin + Dexamethasone, hydrocortisone, methylprednisolone: Co-administered glucocorticoids may decrease the activity of aldesleukin.

Binimetinib + nirmatrelvir/ritonavir (5 days): No effect on binimetinib is anticipated. However, binimetinib is given in combination with encorafenib and coadministration of encorafenib with nirmatrelvir/ritonavir is not recommended.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 25 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Cancer Therapies (C-D)

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Cabazitaxel	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Cabozantinib	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Capecitabine	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Capmatinib	↑	↔	↑	↑	↔	↔	↔	↔	↑	↔
Carboplatin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Carfilzomib	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Cedazuridine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Cemiplimab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Ceritinib	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Cetuximab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Chlorambucil	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Cobimetinib	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Copanlisib	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Crizotinib	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Cyclophosphamide	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Dabrafenib	↓	↔	↓	↓	↔♥	↓	↓	↓	↔	↔
Dacarbazine	↔	↔	↔	↑	↔	↔	↔	↔	↔	↔
Dacomitinib	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Dactinomycin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Daratumumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Darolutamide	↑	↔	↑	↑	↔	↔	↔	↔	↑	↔
Dasatinib	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Decitabine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Docetaxel	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Doxorubicin	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Durvalumab	↔	↔	↔	↔	↔	↓	↓	↓	↓	↓
Duvelisib	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

Baricitinib, tocilizumab: Caution is required due to potential additive haematological toxicity.

Cyclophosphamide + nirmatrelvir/ritonavir: In theory, nirmatrelvir/ritonavir could potentially reduce the risk of neurotoxicity by inhibiting the CYP3A4-mediated inactivation pathway.

Dacarbazine + Nirmatrelvir/ritonavir (≥10 days): When used for an extended treatment duration, nirmatrelvir/ritonavir could increase activation to MTIC and thereby increase the efficacy and toxicity of dacarbazine.

Durvalumab, Ipilimumab + Dexamethasone, Hydrocortisone, Methylprednisolone, Baricitinib, Tocilizumab: A reduction in COVID therapy cannot be excluded due to the immunostimulatory effect of the cancer therapy (which persists even upon discontinuation of the drug).

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 26 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Cancer Therapies (E-H)

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Elotuzumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Enasidenib	↓	↔	↓	↓	↓	↓	↓	↓	↑	↔
Encorafenib	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Enfortumab vedotin	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Entrectinib	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Enzalutamide	↓	↔	↓	↓	↓♥	↓	↓	↓	↔	↔
Epcoritamab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Epirubicin	↑	↔	↑	↓	↔♥	↔	↔	↔	↔	↔
Erdafitinib	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Eribulin	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Erlotinib	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Etoposide	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Exemestane	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Fedratinib	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Fluorouracil (5-FU)	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Flutamide	↑	↔	↑↓	↑↓	↔♥	↔	↔	↔	↔	↔
Fulvestrant	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Gefitinib	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Gemcitabine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Gilteritinib	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Glasdegib	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Hydroxycarbamide (Hydroxyurea)	↔	↔	↑	↑	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

Baricitinib, Tocilizumab: Caution is required due to potential additive haematological toxicity.

Fedratinib + Baricitinib: Coadministration is not recommended due to potential additive immunosuppression and increased risk of infection.

Flutamide + Nirmatrelvir/ritonavir: Coadministration could increase flutamide concentrations but decrease concentrations of an active metabolite. The clinical significance of this interaction is unknown.

Fostamatinib + Ensitrelvir or Nirmatrelvir/ritonavir: Exposure of R406 (fostamatinib's major active metabolite) is expected to increase which may increase the risk of adverse reactions (i.e., diarrhoea, hypertension, hepatotoxicity and neutropenia).

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 27 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Cancer Therapies (I-O)

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Ibrutinib	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Idarubicin	↔	↔	↔	↔	↔					
Idelalisib	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Imatinib	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Infigratinib	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Inotuzumab ozogamicin	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Ipilimumab	↔	↔	↔	↔	↔	↓	↓	↓	↓	↓
Irinotecan	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Isatuximab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Isotretinoin	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Ivosidenib	↑↓	↔	↑↓	↑↓	↓♥	↓	↓	↓	↔	↔
Ixazomib	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Lapatinib	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Larotrectinib	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Lenalidomide	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Lenvatinib	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Letrozole	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Lomustine	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Lorlatinib	↑↓	↔	↑↓	↑↓	↔	↓	↓	↓	↔	↔
Mercaptopurine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Methotrexate	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Midostaurin	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Mitomycin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Mitotane	↓	↔	↓	↓	↓	↓	↓	↓	↔	↔
Mobocertinib	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Necitumumab	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Neratinib	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Nilotinib	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Niraparib	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Nivolumab	↔	↔	↔	↔	↔	↓	↓	↓	↓	↓
Obinutuzumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Ofatumumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Olaparib	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Olaratumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Osimertinib	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Oxaliplatin	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

Baricitinib, Tocilizumab: Caution is required due to potential additive haematological toxicity.

Nivolumab, Pembrolizumab + Dexamethasone, Hydrocortisone, Methylprednisolone, Baricitinib, Tocilizumab: A reduction in COVID therapy cannot be excluded due to the immunostimulatory effect of the cancer therapy (which persists even upon discontinuation of the drug).

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 28 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Cancer Therapies (P-S)

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Paclitaxel	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Palbociclib	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Panitumumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Panobinostat	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Pazopanib	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Pembrolizumab	↔	↔	↔	↔	↔	↓	↓	↓	↓	↓
Pemetrexed	↔	↔	↔	↔	↔	↔	↔	↔	↑↑	↔
Pemigatinib	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Pertuzumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Pexidartinib	↑	↔	↑	↑	↔	↓	↓	↓	↔	↔
Polatuzumab vedotin	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Pomalidomide	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Ponatinib	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Pralsetinib	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Regorafenib	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Relugolix	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Repotrectinib	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Ribociclib	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Ripretinib	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Rituximab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Romidepsin	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Rucaparib	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Selinexor	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Selpercatinib	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Sonidegib	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Sorafenib	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Sotorasib	↑	↔	↓	↓	↔	↓	↓	↓	↔	↔
Sunitinib	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑↑ Potential increased exposure of COVID drug
- ↓↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

Baricitinib, Tocilizumab: Caution is required due to potential additive haematological toxicity.

Rituximab + Baricitinib, Tocilizumab:

Coadministration is not recommended due to potential additive immunosuppression and increased risk of infection.

Sorafenib + Ensitrelvir or Nirmatrelvir/ritonavir: Coadministration of sorafenib and ritonavir in patients with Kaposi sarcoma did not significantly alter the exposure of sorafenib. However, the study had to be terminated early due to poor tolerance, which could possibly be related to inhibition of CYP3A4 by ritonavir leading to the formation of more toxic metabolites.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 29 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Cancer Therapies (T-Z)

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Talazoparib	↔	↔	↑	↑	↔	↔	↔	↔	↔	↔
Tamoxifen	↓	↔	↓	↓	↔♥	↓	↓	↓	↔	↔
Tegafur/ Gimeracil/ Oteracil	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Temsirolimus	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Teniposide	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Tepotinib	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Thalidomide	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Thiotepa	↑↓	↔	↑↓	↑↓	↔	↔	↔	↔	↔	↔
Tisotumab vedotin	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Tivozanib	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Topotecan	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Toremifene	↑♥	↔	↑♥	↑♥	↔♥	↔	↔	↔	↔	↔
Trabectedin	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Trametinib	↔	↔	↔	↔	↔	↔	↔	↔	↑	↔
Trastuzumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Trastuzumab emtansine	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Trifluridine/Tipiracil	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Tucatinib	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Umbralisib	↑↓	↔	↑↓	↑↓	↓	↓	↓	↓	↔	↔
Vandetanib	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Vemurafenib	↑	↔	↑	↑	↔♥	↓	↓	↓	↑	↔
Venetoclax	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Vinblastine	↑	↔	↑	↑	↔	↓	↓	↓	↔	↔
Vincristine	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Vinorelbine	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Zanubrutinib	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

- Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.
- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

Baricitinib, Tocilizumab: Caution is required due to potential additive haematological toxicity.

Tamoxifen + Ensitrelvir or Nirmatrelvir/ritonavir: Exposure of endoxifen (thought to be the most important metabolite contributing to the pharmacologic activity of tamoxifen) may decrease and reduce the efficacy of tamoxifen.

Thiotepa + Ensitrelvir or Nirmatrelvir/ritonavir: Coadministration is expected to increase thiotepa concentrations and decrease concentrations of TEPA (the active alkylating metabolite). This may increase the risk of adverse effects whilst simultaneously reducing efficacy.

Trastuzumab emtansine + Ensitrelvir or Nirmatrelvir/ritonavir: Coadministration is expected to increase concentrations of DM1, an active component of emtansine, can lead to an increase in toxicity.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 30 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Contraceptives/HRT - Contraceptives

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Desogestrel (COC)	↔	↔	↑↓	↑↓	↔	↔	↔	↔	↔	↔
Desogestrel (POP)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Drospirenone (COC)	↔	↔	↑↓	↑↓	↔	↔	↔	↔	↔	↔
Ethinylestradiol	↔	↔	↓	↓	↔	↔	↔	↔	↑ <1%	↔
Etonogestrel (implant)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Etonogestrel (vaginal ring)	↔	↔	↑↓	↑↓	↔	↔	↔	↔	↔	↔
Gestodene (COC)	↔	↔	↑↓	↑↓	↔	↔	↔	↔	↔	↔
Levonorgestrel (COC)	↔	↔	↑↓	↑↓	↔	↔	↔	↔	↓ 12%	↔
Levonorgestrel (emergency con.)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Levonorgestrel (implant)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Levonorgestrel (IUD)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Levonorgestrel (POP)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Medroxyprogesterone (depot inj)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Norelgestromin (patch)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Norethisterone (COC)	↔	↔	↑↓	↑↓	↔	↔	↔	↔	↔	↔
Norethisterone (IM depot)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Norethisterone (POP)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Norgestimate (COC)	↔	↔	↑↓	↑↓	↔	↔	↔	↔	↔	↔
Norgestrel (COC)	↔	↔	↑↓	↑↓	↔	↔	↔	↔	↔	↔
Ulipristal	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

COC – Combined oral contraceptive; POP – Progestogen only pill; IUD – Intra-uterine device

COCs, Etonogestrel vaginal ring + Nirmatrelvir/ritonavir

Coadministration may increase progestogen exposure, but the estrogen component is expected to be reduced. This is unlikely to impair contraceptive efficacy, particularly considering the short duration of nirmatrelvir/ritonavir treatment, though it may increase the risk of irregular bleeding. However, Paxlovid product labels for 5 day administration state patients using combined hormonal contraceptives should be advised to use an effective alternative contraceptive method or an additional barrier method of contraception during treatment with nirmatrelvir/ritonavir, and until one menstrual cycle after stopping nirmatrelvir/ritonavir.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 31 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Contraceptives/HRT - Hormone Replacement Therapy

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Conjugated estrogens	↔	↔	↔	↓	↔	↔	↔	↔	↔	↔
Drospirenone (HRT)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Dydrogesterone (HRT)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Estradiol	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Levonorgestrel (HRT)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Medroxyprogesterone (oral)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Norethisterone (HRT)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Norgestrel (HRT)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Progesterone	↔	↔	↔	↑	↔	↔	↔	↔	↔	↔

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

	These drugs should not be coadministered
	Potential interaction which may require a dose adjustment or close monitoring.
	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 32 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Cough and Cold Preparations

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Benzonatate	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Carbocisteine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Dextromethorphan	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Guaifenesin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Pseudoephedrine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

■	These drugs should not be coadministered
■	Potential interaction which may require a dose adjustment or close monitoring.
■	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
■	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 33 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Covid-19 Antiviral Therapies

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Casirivimab/Imdevimab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Ensitrelvir		↔	↑↑	↑↑	↔	↑	↑	↑	↔	↔
Favipiravir	↔	↔	↔	↔	↔	↔	↔	↔	↑	↔
Molnupiravir	↔		↔	↔	↔	↔	↔	↔	↔	↔
Niclosamide	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Nirmatrelvir/ritonavir (5 days)	↑↑	↔			↔	↔	↔	↔	↔	↔
Nirmatrelvir/ritonavir (≥ 10 days)	↑↑	↔			↔	↔	↔	↔	↔	↔
Nitazoxanide	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Pemivibart	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Remdesivir	↔	↔	↔	↔		↔	↔	↔	↔	↔
Sotrovimab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Tixagevimab/Cilgavimab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑↑ Potential increased exposure of COVID drug
- ↓↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

Ensitrelvir + Dexamethasone

Coadministration of ensitrelvir (750 mg on day 1, 250 mg on day 2-5) with dexamethasone (1 mg) increased dexamethasone AUC by 3.47-fold at day 5, by 2.38-fold at day 9 (5 days after last ensitrelvir dose) and by 1.58-fold at day 14 (10 days after last ensitrelvir dose). The risk of Cushing syndrome is expected to be low due to the low dose of dexamethasone used in COVID-19 treatment and due to the short duration of ensitrelvir treatment. Prescribers should be aware of and to look out for signs of systemic corticosteroid side effects.

Ensitrelvir + Hydrocortisone

The risk of Cushing syndrome is expected to be low due to the low dose and short treatment duration of hydrocortisone used in COVID-19 treatment and due to the short duration of ensitrelvir treatment.

Ensitrelvir + Methylprednisolone

The risk of Cushing syndrome is expected to be low due to the low dose of methylprednisolone used in COVID-19 treatment and due to the short duration of ensitrelvir treatment. Prescribers should be aware of and to look out for signs of systemic corticosteroid side effects.

Pemivibart

Pemivibart is for the pre-exposure prophylaxis of COVID-19 and is not for use in patients with a current COVID-19 infection. However, should patients who have received pemivibart develop a COVID-19 infection, pemivibart is not expected to affect therapies subsequently administered for the treatment of COVID-19.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 34 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Covid-19 Host-directed Therapies

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Anakinra	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Baricitinib	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Budesonide (inhaled)	↑	↔	↔	↔	↔	↔	↔	↔	↔	↔
Canakinumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Covid-19 convalescent plasma	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Covid-19 vaccines	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Dexamethasone (low dose; ≤16 mg)	↑ 247%	↔	↔	↔	↔	↔	↔	↔	↔	↔
Fluvoxamine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Hydrocortisone (oral or IV)	↑	↔	↔	↔	↔	↔	↔	↔	↔	↔
Imatinib (14 days)	↑	↔	↑	↑	↔ ♥	↔	↔	↔	↔	↔
Infliximab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Methylprednisolone (oral or IV)	↑	↔	↔	↔	↔	↔	↔	↔	↔	↔
Ruxolitinib	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Sarilumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Tocilizumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Vilobelimab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

- Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.
- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

Baricitinib or Tocilizumab and other immune therapies

Coadministration of some immune therapies is not recommended due to the enhanced immunosuppressive effect and/or the risk of serious infections or additive haematological toxicity.

Baricitinib or Tocilizumab + Imatinib

Caution is required due to potential additive haematological toxicity.

Budesonide + Nirmatrelvir/ritonavir

Budesonide concentrations are expected to increase due to CYP3A4 inhibition by nirmatrelvir/ritonavir. However, unlike with other strong CYP3A4 inhibitors, this is unlikely to be clinically relevant due to the short duration of nirmatrelvir/ritonavir treatment.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 35 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made.

Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Cystic Fibrosis Agents

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Ivacaftor	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Ivacaftor/lumacaftor	↓	↔	↓	↓	↓	↓	↓	↓	↓	↔
Ivacaftor/tezacaftor	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Ivacaftor/tezacaftor/elexacaftor	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 36 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Dementia Therapies

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Donepezil	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Ergoloid mesylates	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Galantamine	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Memantine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Rivastigmine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 37 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Erectile Dysfunction Agents

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Alprostadil	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Avanafil	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Sildenafil (erectile dysfunction)	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Tadalafil (erectile dysfunction)	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Vardenafil	↑	↔	↑	↑	↔ ♥	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 38 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Gastrointestinal Agents

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Alosetron	↔	↔	↓	↓	↔	↔	↔	↔	↔	↔
Antacids	↔	↔	↔	↔	↔	↓	↓	↓	↔	↔
Bisacodyl	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Bismuth subsalicylate	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Cimetidine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Cisapride	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Dexlansoprazole	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Dicycloverine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Docusate	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Esomeprazole	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Famotidine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Hyoscine butylbromide	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Ispaghula husk	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Lactulose	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Lansoprazole	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Linacotide	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Loperamide	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Macrogol (Polyethylene Glycol 3350)	↓	↓	↓	↓	↔	↓	↓	↓	↓	↔
Magnesium salts (oral)	↔	↔	↔	↔	↔	↓	↓	↓	↔	↔
Mebeverine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Mesalazine (mesalamine)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Naloxegol	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Nizatidine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Psyllium husk	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Octreotide	↑	↔	↑	↑	↔	↔	↑	↑	↔	↔
Omeprazole	↔	↔	↔	↔	↔	↔	↔	↔	↑ 7%	↔
Pantoprazole	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Prucalopride	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Rabeprazole	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Ranitidine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Roxatidine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Senna	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Sucralfate	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

Antacids + Dexamethasone (oral), Hydrocortisone, Methylprednisolone

Administration of oral dexamethasone, hydrocortisone or methylprednisolone and antacids should be separated by 2 hours.

Bisacodyl, Lactulose, Prucalopride, Senna + Dexamethasone, Hydrocortisone, Methylprednisolone

Close monitoring is advised as dexamethasone, hydrocortisone, methylprednisolone and laxatives may cause hypokalaemia (mainly in cases of laxative misuse/overdose) which increases the risk of torsade de pointes. Before the start of corticosteroid treatment, hypokalaemia should be corrected and patients should be monitored clinically, for electrolyte imbalance and by ECG.

Magnesium salts + Dexamethasone (oral), Hydrocortisone, Methylprednisolone

Administration of oral dexamethasone, hydrocortisone or methylprednisolone and magnesium salts should be separated by 2-4 hours.

Mesalazine + Baricitinib, Tocilizumab: Caution is required due to potential additive haematological toxicity.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 39 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Gastrointestinal Agents – Anti-emetics

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Aprepitant	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Cyclizine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Dolasetron	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Domperidone	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Dronabinol	↔	↔	↔	↑↓	↔	↔	↔	↔	↔	↔
Fosaprepitant	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Granisetron	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Hyoscine (Scopolamine)	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Hyoscine hydrobromide	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Metoclopramide	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Netupitant	↑	↔	↑	↑	↔	↑	↔	↔	↔	↔
Ondansetron	↔	↔	↔	↔	↔♥	↔	↔	↔	↑♥	↔
Palonosetron	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Prochlorperazine	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Rolapitant	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Tropisetron	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

- Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.
- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

Netupitant + Dexamethasone

When netupitant (300 single oral dose) and dexamethasone (20 mg on day 1 followed by 8 mg twice daily on days 2 to 4) were coadministered, dexamethasone mean AUC and Cmax increased by 72% and 11% on day 1 and by 138% and 75% on day 4. Although product labels for netupitant (in combination with palonosetron) recommend a dose reduction for dexamethasone, no a priori dose reduction is necessary when dexamethasone is used at a low dose for the treatment of COVID-19 infection.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 40 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

HCV DDAs

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Elbasvir/Grazoprevir	↔	↔	↑	↑	↔	↔	↔	↔	↔	↔
Glecaprevir/Pibrentasvir	↔	↔	↑	↑	↔	↔	↔	↔	↔	↔
Ledipasvir/Sofosbuvir	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Ombitasvir/Paritaprevir/r	↔	↔	↑	↑	↔	↔	↔	↔	↔	↔
Ombitasvir/Paritaprevir/r + Dasabuvir	↔	↔	↑	↑	↔	↔	↔	↔	↔	↔
Sofosbuvir	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Sofosbuvir/Velpatasvir	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Sofosbuvir/Velpatasvir/Voxilaprevir	↔	↔	↑	↑	↔	↔	↔	↔	↔	↔

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

Ombitasvir/Paritaprevir/r ± Dasabuvir + Ensitrelvir

Ensitrelvir and ritonavir are strong inhibitors of CYP3A4. Ensitrelvir is unlikely to significantly alter ombitasvir, paritaprevir or dasabuvir given that ritonavir already strongly inhibits CYP3A4. Similarly, ritonavir is unlikely to significantly alter ensitrelvir given that ensitrelvir already strongly inhibits CYP3A4.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 41 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

HIV Antiretroviral Therapies

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Abacavir	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Albuvirtide	↔	↔	↓	↓	↔	↔	↔	↔	↔	↔
Atazanavir alone	↑	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Atazanavir + ritonavir	↑	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Atazanavir/cobicistat	↑	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Bictegravir/emtricitabine/TAF	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Cabotegravir (oral)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Cabotegravir/rilpivirine (long acting)	↔	↔	↔	↔	↔♥	↓	↔	↔	↔	↔
Darunavir + ritonavir	↑	↔	↔	↔	↔	↔	↔	↔	↔	↔
Darunavir/cobicistat	↑	↔	↔	↔	↔	↔	↔	↔	↔	↔
Darunavir/cobi/emtricitabine/TAF	↑	↔	↔	↔	↔	↔	↔	↔	↔	↔
Dolutegravir	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Dolutegravir/lamivudine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Dolutegravir/rilpivirine	↔	↔	↔	↔	↔♥	↓ (RPV)	↔	↔	↔	↔
Dolutegravir/abacavir/lamivudine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Doravirine	↔	↔	↔	↔	↔	↓	↔	↔	↔	↔
Doravirine/lamivudine/TDF	↔	↔	↔	↔	↔	↓ (DOR)	↔	↔	↔	↔
Efavirenz	↓	↔	↓ (RTV)	↓ (RTV)	↔♥	↓	↓	↓	↔	↔
Elvitegravir/cobi/emtricitabine/TAF	↑	↔	↔	↔	↔	↔	↔	↔	↔	↔
Elvitegravir/cobi/emtricitabine/TDF	↑	↔	↔	↔	↔	↔	↔	↔	↔	↔
Emtricitabine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Emtricitabine/tenofovir alafenamide	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Emtricitabine/tenofovir-DF	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Etravirine	↓	↔	↔	↔	↔	↓	↓	↓	↔	↔
Fostemsavir	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Ibalizumab-uyk	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Lamivudine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Lenacapavir	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Lopinavir/ritonavir	↑	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Maraviroc	↑	↔	↑	↑	↔	↓	↔	↔	↔	↔
Nevirapine	↓	↔	↓ (RTV)	↓ (RTV)	↔	↓	↓	↓	↔	↔
Raltegravir	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Rilpivirine	↔	↔	↔	↔	↔♥	↓	↔	↔	↔	↔
Rilpivirine/emtricitabine/TAF	↔	↔	↔	↔	↔♥	↓ (RPV)	↔	↔	↔	↔
Rilpivirine/emtricitabine/TDF	↔	↔	↔	↔	↔♥	↓ (RPV)	↔	↔	↔	↔
Tenofovir-DF	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Zidovudine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

Dexamethasone: Note, any reduction in comedication concentrations may persist for up to 14 days after dexamethasone course is complete.

Cobicistat or ritonavir containing regimens + Nirmatrelvir/ritonavir

No dosage modification required but patients should be informed about the potential occurrence of adverse effects due to additional ritonavir.

Dolutegravir/Rilpivirine, Rilpivirine, Rilpivirine/Emtricitabine/TAF + Dexamethasone.

Dexamethasone is a dose dependent CYP3A4 inducer and may decrease rilpivirine concentrations due to induction of CYP3A4. Although the level of induction at the dose recommended for COVID (6 mg/day) is likely to be relatively modest, we advise either using hydrocortisone (IV, 200 mg/day) or, alternatively, giving dexamethasone but doubling the dose of rilpivirine to 50 mg once daily. This dose should be maintained for ~ 2 weeks after the end of treatment as any reduction in rilpivirine concentrations may persist for up to 14 days after stopping dexamethasone.

Zidovudine + Baricitinib, Tocilizumab: Use with caution due to potential additive toxicity.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 42 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Hypertensives – ACE inhibitors

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Benazepril	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Captopril	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Cilazapril	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Enalapril	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Fosinopril	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Lisinopril	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Moexipril	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Perindopril	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Quinapril	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Ramipril	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Trandolapril	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.
♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Hypertensives – Angiotensin antagonists

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Azilsartan	↔	↔	↔	↓	↔	↔	↔	↔	↔	↔
Candesartan	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Eprosartan	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Irbesartan	↔	↔	↓	↓	↔	↔	↔	↔	↔	↔
Losartan	↔	↔	↑	↑	↔	↔	↔	↔	↔	↔
Olmesartan	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Telmisartan	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Valsartan	↔	↔	↑	↑	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.
♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

Losartan + Nirmatrelvir/ritonavir

Nirmatrelvir/ritonavir could potentially increase the conversion to the more pharmacologically active metabolite.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 43 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Hypertensives – Diuretics

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Amiloride	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Bendroflumethiazide	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Bumetanide	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Chlortalidone (Chlorthalidone)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Furosemide	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Hydrochlorothiazide	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Indapamide	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Metolazone	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Torasemide	↔	↔	↓	↓	↔	↔	↔	↔	↔	↔
Triamterene	↔	↔	↓	↓	↔	↔	↔	↔	↔	↔
Xipamide	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

Bendroflumethiazide, Chlortalidone, Furosemide, Hydrochlorothiazide, Indapamide, Metolazone, Torasemide, Xipamide + Dexamethasone, Hydrocortisone, Methylprednisolone

Close monitoring of potassium levels is advised as dexamethasone, hydrocortisone or methylprednisolone may cause hypokalaemia, the effect of which will be enhanced by the diuretic. In cases of hypokalaemia, potassium levels should be corrected.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 44 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Hypertensives – Other agents

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Aliskiren	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Clonidine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Dopamine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Doxazosin	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Eplerenone	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Finerenone	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Glyceryl trinitrate (Nitroglycerin)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Hydralazine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Isosorbide dinitrate	↓	↔	↓	↓	↔	↔	↔	↔	↔	↔
Ivabradine	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Labetalol	↔	↔	↓	↓	↔	↔	↔	↔	↔	↔
Lacidipine	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Lercanidipine	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Methyldopa	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Minoxidil	↔	↔	↔	↓	↔	↔	↔	↔	↔	↔
Moxonidine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Nicorandil	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Prazosin	↔	↔	↔	↑	↔	↔	↔	↔	↔	↔
Ranolazine	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Sacubitril	↔	↔	↑	↑	↔	↔	↔	↔	↔	↔
Sodium nitroprusside	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Spirolactone	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Terazosin	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

Isosorbide dinitrate + Ensitrelvir or Nirmatrelvir/ritonavir

Production of the active substance, nitric oxide, may be reduced.

Sacubitril + Nirmatrelvir/ritonavir

Exposure of sacubitril's active metabolite may be increased.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 45 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Hypertensives – Pulmonary hypertension

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Ambrisentan	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Bosentan	↑	↔	↑	↑	↔	↓	↓	↓	↔	↔
Epoprostenol	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Iloprost	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Macitentan	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Riociguat	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Selexipag	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Sildenafil	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Tadalafil	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Treprostinil	↔	↔	↔	↓	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 46 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Illicit/Recreational

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Alcohol	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Amphetamine	↔	↔	↑	↑	↔	↔	↔	↔	↔	↔
Cannabis (Marijuana)	↔	↔	↑	↑	↔	↔	↔	↔	↔	↔
Carfentanil	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Cocaine	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Ecstasy (MDMA)	↔	↔	↑	↑	↔	↔	↔	↔	↔	↔
Enobosarm (Ostarine)	↔	↔	↔	↓	↔	↔	↔	↔	↔	↔
GHB (Gamma-hydroxybutyrate)	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Heroin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
LSD (Lysergic acid diethylamide)	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Mephedrone	↔	↔	↑	↑	↔	↔	↔	↔	↔	↔
Methamphetamine	↔	↔	↑	↑	↔	↔	↔	↔	↔	↔
Methylone	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Monkey dust	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Nitazenes	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Poppers (Amyl nitrate)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Psilocybin	↔	↔	↔	↓	↔	↔	↔	↔	↔	↔
Trenbolone	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

Carfentanil

Carfentanil is an extremely strong opiate, reported to be up to 10,000 times more potent than morphine, and multiple deaths have resulted from its use. Advise patients to avoid.

Heroin + Nirmatrelvir/ritonavir

Coadministration may potentiate the effects of opiate in the CNS (via inhibition of P-gp at the blood-brain barrier). Monitor for opiate toxicity.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 47 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Immune Modulators

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Interferon beta	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Interferon gamma-1b	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

Baricitinib, Tocilizumab

Additional monitoring should be considered as there may be a risk of additive haematological toxicity.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 48 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Immunosuppressants

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Abatacept	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Abrocitinib	↔	↔	↔	↓	↔	↔	↔	↔	↔	↔
Adalimumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Anti-thymocyte globulin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Apremilast	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Azathioprine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Basiliximab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Belatacept	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Belimumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Bimekizumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Certolizumab pegol	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Ciclosporin (Cyclosporine)	↑	↔	↑	↑	↔	↓	↔	↔	↑ 29%	↓
Dimethyl fumarate	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Etanercept	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Everolimus	↑	↔	↑	↑	↔	↓	↔	↔	↔	↔
Filgotinib	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Golimumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Ixekizumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Leflunomide	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Methotrexate	↑	↔	↔	↔	↔	↔	↔	↔	↔	↔
Mycophenolate	↔	↔	↕	↕	↔	↔	↔	↔	↔	↔
Pirfenidone	↔	↔	↓	↓	↔	↔	↔	↔	↔	↔
Risankizumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Secukinumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Sirolimus	↑	↔	↑	↑	↔	↓	↔	↔	↔	↓
Tacrolimus	↑	↔	↑	↑	↔ ♥	↓	↔	↔	↔	↓
Tildrakizumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Tofacitinib	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Upadacitinib	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Ustekinumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Vedolizumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Voclosporin	↑	↔	↑	↑	↔ ♥	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

- Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.
- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

Baricitinib, Tocilizumab: Coadministration may not be recommended due to potential additive immunosuppression, increased risk of infection and/or additive haematological toxicity. Alternatively, caution (and additional monitoring) may be required due to additive haematological toxicity. See www.covid19-druginteractions.org for details.

Ciclosporin, Everolimus, Sirolimus, Tacrolimus + Dexamethasone

Any reduction in comedication concentrations may persist for up to 14 days after dexamethasone course is complete.

Ciclosporin + Nirmatrelvir/ritonavir:

Management of this interaction is challenging and would require dosage adjustment and therapeutic drug monitoring of ciclosporin which may not be possible given the short duration of nirmatrelvir/ritonavir treatment. An alternative COVID treatment will need to be considered. If TDM is available, see www.covid19-druginteractions.org for details of dose modifications and TDM schedule.

Everolimus, Sirolimus + Nirmatrelvir/ritonavir:

A large increase in everolimus and sirolimus exposure is predicted in presence of NMV/r. Avoid use of NMV/r unless close monitoring of everolimus and sirolimus concentrations is feasible. If TDM is available, see www.covid19-druginteractions.org for details of dose modifications and TDM schedule.

Tacrolimus + Nirmatrelvir/ritonavir:

Management of this interaction is challenging and would require a substantial reduction in tacrolimus dosage. Consider an alternative COVID treatment. If TDM is available, see www.covid19-druginteractions.org for details of dose modifications and TDM schedule.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 49 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made.

Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Inotropes & Vasopressors

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Adrenaline (Epinephrine)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Desmopressin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Dobutamine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Noradrenaline	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Vasopressin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 50 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Lipid Lowering Agents

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Alirocumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Atorvastatin	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Bempedoic acid	↔	↔	↔	↓	↔	↔	↔	↔	↔	↔
Bezafibrate	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Clofibrate	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Colesevelam	↓	↓	↓	↓	↔	↓	↓	↓	↓	↔
Colestyramine (cholestyramine)	↓	↓	↓	↓	↔	↓	↓	↓	↓	↔
Evolocumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Ezetimibe	↔	↔	↔	↕	↔	↔	↔	↔	↔	↔
Fenofibrate	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Fish oils	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Fluvastatin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Gemfibrozil	↔	↔	↔	↓	↔	↔	↔	↔	↔	↔
Icosapent ethyl	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Inclisiran	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Lomitapide	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Lovastatin	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Omega-3 fatty acids	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Pitavastatin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Pravastatin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Rosuvastatin	↑ 65%	↔	↑ 112%	↑	↔	↔	↔	↔	↔	↔
Simvastatin	↑	↔	↑	↑	↔	↔	↔	↔	↓ 17%	↓ 57%

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

Atorvastatin + Ensitrelvir

If possible, pause atorvastatin during ensitrelvir treatment and for up to 10 days after the last dose ensitrelvir.

Bempedoic acid + Baricitinib or Tocilizumab

Caution is required due to potential additive haematological toxicity.

Lovastatin, Simvastatin + Ensitrelvir

The statin should be stopped at least 12 hours prior to initiation of ensitrelvir and not resumed until 10 days post last dose of ensitrelvir.

Atorvastatin, Rosuvastatin + Nirmatrelvir/ritonavir

If possible, the statin should be stopped for the duration of nirmatrelvir/ritonavir therapy and restarted at least 3 days after the last dose of nirmatrelvir/ritonavir.

Note, rosuvastatin PK data from rosuvastatin (10 mg, single dose) and nirmatrelvir/ritonavir (300/100 mg twice daily for 3 doses) in 12 subjects.

Lovastatin, Simvastatin + Nirmatrelvir/ritonavir

The statin should be stopped at least 12 hours prior to initiation of nirmatrelvir/ritonavir therapy and restarted at least 3 days after the last dose of nirmatrelvir/ritonavir but preferably 5 days after completing nirmatrelvir/ritonavir treatment due to the large inter-individual variability in the disappearance of CYP3A4 inhibition.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 51 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Multiple Sclerosis Agents

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Alemtuzumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Baclofen	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Cladribine	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Dantrolene sodium	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Dimethyl fumarate	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Fampridine (Dalfampridine)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Fingolimod	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Glatiramer acetate	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Natalizumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Ocrelizumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Ozanimod	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Peginterferon beta-1a	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Siponimod	↔	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Teriflunomide	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

- Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.
- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

Alemtuzumab, Cladribine, Natalizumab, Ocrelizumab, Ozanimod, Teriflunomide + Baricitinib, Tocilizumab
Caution is advised due to the potential for enhanced immunosuppression with the combination.

Fingolimod + Baricitinib, Tocilizumab

Additional immunosuppressive therapies, such as baricitinib or tocilizumab, should be used with caution with fingolimod, due to additive effects.

Peginterferon beta-1a + Baricitinib, Tocilizumab

Additional monitoring should be considered as there may be a risk of additive haematological toxicity.

Siponimod + Dexamethasone, Hydrocortisone, Methylprednisolone

Caution is advised when administering with another immunosuppressant, such as these corticosteroids, due to possible additive effect.

Siponimod + Baricitinib, Tocilizumab

Caution is advised when administering with another immunosuppressant, such as baricitinib or tocilizumab, due to possible additive effect.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 52 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Ophthalmological Agents

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Brimonidine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Brinzolamide	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Brolucizumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Latanoprost	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Ranibizumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Travoprost	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

■	These drugs should not be coadministered
■	Potential interaction which may require a dose adjustment or close monitoring.
■	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
■	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 53 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Others (A-F)

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Acetazolamide	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Acetylcysteine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Acitretin	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Activated charcoal	↓	↓	↓	↓	↔	↓	↓	↓	↓	↔
Allopurinol	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Atropine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Benralizumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Bethahistine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Birch tree pollen allergen extract	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Bromocriptine	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Cannabidiol	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Carbimazole	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Cinacalcet	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Clomifene	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Colchicine	↑	↔	↑	↑	↔	↓	↔	↔	↔	↔
Crizanlizumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Cytisine (Cytisinicline)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Darbepoetin alfa	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Deferasirox	↔	↔	↔	↓	↔	↔	↔	↔	↔	↔
Denosumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Disulfiram	↑↓	↔	↑↓	↔	↔	↔	↔	↔	↔	↔
Drotaverine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Dupilumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Elagolix	↑	↔	↑	↑	↔	↓	↓	↓	↔	↔
Epoetin alfa	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Epoetin beta	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Ergometrine (Ergonovine)	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Febuxostat	↔	↔	↔	↓	↔	↔	↔	↔	↔	↔
Fezolinetant	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Filgrastim	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Finasteride (1 mg)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Flibanserin	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

Baricitinib, Tocilizumab: Caution is required due to potential additive haematological toxicity.

Birch tree pollen allergen extract + Baricitinib, Tocilizumab: Baricitinib and tocilizumab are immunosuppressants and some product labels contraindicate administration of birch tree pollen allergen in patients with immunosuppression.

Alfuzosin + Nirmatrelvir/ritonavir: Given the short duration of nirmatrelvir/ritonavir treatment, alfuzosin should be stopped for the duration of nirmatrelvir/ritonavir therapy and restarted 3 days after the last dose of nirmatrelvir/ritonavir.

Clomifene + Nirmatrelvir/ritonavir: Potential for limited increase in clomifene concentrations and decrease in concentrations of the active metabolite.

Disulfiram + Ensitrelvir or Nirmatrelvir/ritonavir: Conversion to the active metabolite/product may be inhibited, leading to a reduced clinical effect. No effect on disulfiram expected with NMV/r ≥10 days due to the mixed effect on CYP3A4 (inhibition) and UGT (induction).

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 54 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Others (G-O)

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Glacial acetic acid (topical)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Goserelin	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Grass pollen allergen extract	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Hexobarbital	↓	↔	↓	↓	↓	↓	↓	↓	↔	↓
House dust mite allergen extract	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Interferon beta	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Isosorbide mononitrate	↑↓	↔	↑↓	↑↓	↔	↔	↔	↔	↔	↔
Ivermectin	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Leuprorelin	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Levothyroxine	↔	↔	↔	↓	↔	↓	↓	↓	↔	↔
Liothyronine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Magnesium sulphate (IV)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Melatonin	↔	↔	↔	↓	↔	↔	↔	↔	↔	↔
Mepolizumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Methylethylgometriner	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Midodrine	↔	↔	↑	↑	↔	↔	↔	↔	↔	↔
Misoprostol	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Modafinil	↑↓	↔	↔	↔	↔	↓	↓	↓	↔	↔
Naftidrofuryl	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Naloxone	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Naltrexone	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Neostigmine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Nicotine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Nintedanib	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Omalizumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Orlistat	↓	↓	↓	↓	↔	↓	↓	↓	↓	↔
Ospemifene	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

- Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.
- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

Baricitinib, Tocilizumab:

Caution is required due to potential additive haematological toxicity.

House dust mite allergen extract + Baricitinib, Tocilizumab: Baricitinib and tocilizumab are immunosuppressants and administration of house dust mite allergen is contraindicated in patients with immunosuppression.

Isosorbide mononitrate + Ensitrelvir or Nirmatrelvir/ritonavir: Conversion to the active metabolite/product may be inhibited, leading to a reduced clinical effect. No effect on disulfiram expected with NMV/r ≥10 days due to the mixed effect on CYP3A4 (inhibition) and UGT (induction).

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 55 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Others (P-Z)

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Pancreatic enzymes (Creon)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Pentosan polysulfate sodium	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Pentoxifylline	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Phentermine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Phenylephrine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Pilocarpine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Piracetam	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Pitolisant	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Potassium	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Probenecid	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Propylthiouracil	↔	↔	↔	↓	↔	↔	↔	↔	↔	↔
Pyridostigmine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Raloxifene	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Ramelteon	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Riluzole	↔	↔	↓	↓	↔	↔	↔	↔	↔	↔
Sevelamer	↓	↓	↓	↓	↔	↓	↓	↓	↓	↔
Sodium phosphate	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Sodium zirconium cyclosilicate	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Sulfasalazine	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Tasimelteon	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Telotristat	↓	↔	↓	↓	↔	↓	↓	↓	↔	↔
Tenapanor	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Thiamazole (Methimazole)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Tolvaptan	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Triclabendazole	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Triptorelin	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Ursodeoxycholic acid (Ursodiol)	↔	↔	↔	↔	↔	↓	↓	↓	↔	↔
Varenicline	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Zileuton	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

Baricitinib, Tocilizumab:

Caution is required due to potential additive haematological toxicity.

Pitolisant + Ensitrelvir, Nirmatrelvir/ritonavir

The effect of CYP3A4 inhibitors on pitolisant exposure in CYP2D6 poor metabolizers is unknown.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 56 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Overactive Bladder Agents

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Darifenacin	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Fesoterodine	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Mirabegron	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Oxybutynin	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Solifenacin	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Tolterodine	↑	↔	↑	↑	↔♥	↔	↔	↔	↔	↔
Trospium	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 57 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Parkinsonism Agents

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Amantadine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Apomorphine	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔
Benserazide/levodopa	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Benzatropine (Benztropine)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Biperiden	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Cabergoline	↔	↔	↑	↑	↔	↔	↔	↔	↔	↔
Carbidopa	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Carbidopa/levodopa	↔	↔	?	?	↔	↔	↔	↔	↔	↔
Entacapone	↔	↔	↔	↓	↔	↔	↔	↔	↔	↔
Levodopa	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Orphenadrine	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Piribedil	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Pramipexole	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Procyclidine	↑	↔	↑	↑↓	↔	↔	↔	↔	↔	↔
Rasagiline	↔	↔	↔	↓	↔	↔	↔	↔	↔	↔
Ropinirole	↔	↔	↔	↓	↔	↔	↔	↔	↔	↔
Rotigotine	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Safinamide	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Selegiline	↔	↔	↓	↓	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

Carbidopa/levodopa + Nirmatrelvir/ritonavir:

Enhanced levodopa effects including severe dyskinesias were described in a case report after initiation of an antiretroviral regimen containing indinavir to an individual who was previously stable on levodopa/carbidopa therapy. Based on this isolated case, the risk of an interaction with ritonavir is unclear.

Procyclidine + Nirmatrelvir/ritonavir (≥10 days):

When nirmatrelvir/ritonavir is used for an extended treatment duration (10 days or longer), ritonavir could increase procyclidine exposure by CYP inhibition but may induce glucuronidation thereby mitigating the inhibitory effect. The clinical relevance of the interaction is unknown.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 58 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Steroids

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
Beclometasone	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Betamethasone	↑	↔	↔	↑	↔	↓	↓	↓	↔	↔
Betamethasone (topical)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Budesonide (oral/rectal)	↑	↔	↔	↑	↔	↔	↔	↔	↔	↔
Ciclesonide	↑	↔	↔	↑	↔	↔	↔	↔	↔	↔
Clobetasol	↑	↔	↔	↑	↔	↔	↔	↔	↔	↔
Cortisone	↑	↔	↔	↑	↔	↔		↔	↔	↔
Cortisone (topical)	↔	↔	↔	↔	↔	↔		↔	↔	↔
Deflazacort	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Dexamethasone (>16 mg)	↑	↔	↑	↑	↔		↓	↓	↔	↔
Difluprednate	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Fludrocortisone	↑	↔	↔	↑	↔	↔	↔	↔	↔	↔
Flunisolide	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Fluocinolone	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Fluticasone	↑	↔	↔	↑	↔	↔	↔	↔	↔	↔
Hydrocortisone (topical)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Megestrol acetate	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Methylprednisolone (topical)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Mometasone	↑	↔	↔	↑	↔	↔	↔	↔	↔	↔
Nandrolone	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Oxandrolone	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Oxymetholone	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Prednisolone	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Prednisone	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Stanozolol	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Testosterone	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Triamcinolone	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

- ♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates



Interactions with Key COVID-19 Therapies

Revised January 2026

Page 59 of 59

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

Management of interactions with nirmatrelvir/ritonavir (Paxlovid) may be complex and full details should be obtained from the website.

Vitamins/Supplements/Herbals

	Antivirals					Corticosteroids			Host-directed	
	ESV	MOL	NMV/r 5 days	NMV/r ≥10 days	RDV	DEX	HC	MP	BAR	TCZ
African potato	?	↔	↔	↔	↔	↔	↔	↔	↓	↔
Ayahuasca	↔	↔	↑	↑	↔	↔	↔	↔	↔	↔
Cat's claw (Uncaria tomentosa)	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
Enteral feeds	↔	↔	↔	↔	↔	↓	↓	↓	↔	↔
Garlic	↓	↔	↓	↓	↔	↓	↓	↓	↔	↔
Ginkgo biloba	↓	↔	↔	↔	↔	↓	↓	↓	↔	↔
Guggulsterone	↓	↔	↓	↓	↔	↓	↓	↓	↔	↔
Liquorice (Glycyrrhiza glabra)	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Malabar nut tree	↓	↔	↓	↓	↔	↓	↓	↓	↔	↔
Oral nutritional supplements	↔	↔	↔	↔	↔	↓	↓	↓	↔	↔
Quercetin	?	↔	?	?	↔	↔	↔	↔	↔	↔
Red yeast rice	↑	↔	↑	↑	↔	↔	↔	↔	↔	↔
St John's wort	↓	↔	↓	↓	↓	↓	↓	↓	↔	↔

Text Legend

- ↑ Potential increased exposure of the comedication
- ↓ Potential decreased exposure of the comedication
- ↑ Potential increased exposure of COVID drug
- ↓ Potential decreased exposure of COVID drug
- ↔ No significant effect

Numbers refer to increase/decrease in AUC as observed in drug-drug interaction studies.

♥ This interaction involves drugs identified by www.crediblemeds.org as having a known, possible or conditional risk of QT prolongation and/or TdP. Risk may be related to dose or concentration (due to DDIs) and/or additive if two or more such drugs are combined. Note, please check product labels for any additional cardiac warnings.

Notes:

African potato + Ensitrelvir:

The clinical relevance of the inducing effect of African potato is unknown as ensitrelvir is a strong inhibitor of CYP3A4 and may compensate the inducing effect. No dose adjustment is required.

Quercetin

Quercetin has the ability to modulate CYP/P-gp activities although there are inconsistencies in literature which make it difficult to predict the nature and magnitude of any interaction. Use with caution and monitor patients carefully for signs of toxicity.

Enteral feeds and Oral Nutritional Supplements

Enteral feeds and oral nutritional supplements contain polyvalent cations which may reduce absorption of orally administered glucocorticoids. Where possible, administration of orally administered glucocorticoids and enteral feeds or oral nutritional supplements should be separated by two to four hours.

No interactions are expected with the COVID-19 therapies listed and the following vitamins/supplements/herbals:

Beta-alanine	Ginger (Zingiber officinale)	Vitamin A (Retinol)
Branched chain amino acids	Ginseng (P ginseng, P quinquefolis)	Vitamin B1 (Thiamine)
Caffeine (anhydrous powder)	Glucosamine	Vitamin B12 (Cyanocobalamin)
Calcium supplements	Grapefruit juice	Vitamin B2 (Riboflavin)
Coenzyme Q10 (Ubidecarenone)	Homeopathic remedies	Vitamin B3 (Niacin, nicotinic acid)
Collagen hydrolysate	Hops (Humulus lupulus)	Vitamin B6 (Pyridoxine)
Creatine monohydrate	Iodine	Vitamin B7 (Biotin)
Cubeb pepper (Piper cubeba)	Iron supplements	Vitamin C (Ascorbic Acid)
Ecdysterone	Liquorice (Glycyrrhiza glabra)	Vitamin D2 (Ergocalciferol)
Echinacea	Milk thistle (Silymarin)	Vitamin D3 (Colecalciferol)
Ferrous fumarate	Multivitamins	Vitamin E (Tocopherol)
Ferrous sulfate	Nicotinamide (Niacinamide)	Vitamin K (Phytomenadione)
Folic acid	Turmeric (Curcumin)	Whey protein
	Valerian	Zinc

Abbreviations

ESV	Ensitrelvir	DEX	Dexamethasone
MOL	Molnupiravir	HC	Hydrocortisone
NMV/r	Nirmatrelvir/ritonavir	MP	Methylprednisolone
RDV	Remdesivir	BAR	Baricitinib
		TCZ	Tocilizumab

Colour Legend

Red	These drugs should not be coadministered
Orange	Potential interaction which may require a dose adjustment or close monitoring.
Yellow	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment unlikely to be required.
Green	No clinically significant interaction expected

Check for Updates

Using a saved or printed version?
Click or scan to check for updates

